Brad Broussard, MD
Internal Medicine · Lafayette, LANPI 1275551509
Payments from drug & device makers
Across 608 payments — averaging $28.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- GSK$3K
- Intuitive Surgical$3K
- Sanofi$877
- Boehringer Ingelheim$734
- Regeneron Healthcare Solutions, Inc.$676
- plus $4K from 35 others
What the payments were for
- Speaking & faculty fees$3,50020%
- Travel & lodging$1521%
- Food & beverage$11,07664%
- Education$2,61615%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 78 | $5,048 |
| GSK | 228 | $3,378 |
| Intuitive Surgical | 4 | $2,776 |
| Sanofi | 31 | $877 |
| Boehringer Ingelheim | 41 | $734 |
| Regeneron Healthcare Solutions, Inc. | 27 | $676 |
| Grifols USA, LLC | 20 | $395 |
| Mylan Specialty L.p. | 17 | $351 |
| Insmed, Inc. | 18 | $303 |
| Amgen | 16 | $302 |
| Mallinckrodt Hospital Products Inc. | 9 | $302 |
| Actelion Pharmaceuticals US, Inc. | 13 | $262 |
| Bayer | 14 | $245 |
| Getinge USA Sales, LLC | 9 | $224 |
| Novartis | 12 | $206 |
| Genentech USA, Inc. | 9 | $181 |
| United Therapeutics Corporation | 7 | $127 |
| Gilead | 7 | $108 |
| E.r. Squibb & Sons, L.L.C. | 7 | $107 |
| AbbVie(2 entities) | 4 | $72 |
| Merck | 3 | $67 |
| ANI Pharmaceuticals, Inc. | 2 | $60 |
| Astellas Pharma US Inc | 3 | $59 |
| Viatris Specialty LLC | 3 | $57 |
| Verona Pharma, Inc. | 3 | $56 |
| Johnson & Johnson | 3 | $44 |
| Teva Pharmaceuticals USA, Inc. | 3 | $44 |
| Fisher & Paykel Healthcare Inc | 2 | $30 |
| Philips North America LLC | 2 | $30 |
| Paratek Pharmaceuticals, Inc. | 2 | $28 |
| Pulmonx Corporation | 1 | $25 |
| Pfizer | 1 | $25 |
| Liquidia Technologies, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Phadia US Inc. | 1 | $17 |
| Livanova USA, Inc. | 1 | $15 |
| Melinta Therapeutics, LLC | 1 | $13 |
| Circassia Inc. | 1 | $13 |
| EKOS Corporation | 1 | $12 |
| Abiomed | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$2,770
- BREZTRI$1,959
- BREZTRI AEROSPHERE$1,772
How this compares
$17,344 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 12 | $159,074 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $127,459 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 101 | $78,904 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $13,086 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $9,208 |
| Incruse ElliptaUmeclidinium Bromide | 22 | $7,155 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $5,820 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 50 | $1,915 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,816 |
| BreynaBudesonide/Formoterol Fumarate | 11 | $1,416 |
| Roflumilast | 12 | $1,174 |
| Azelastine Hcl | 14 | $698 |
| Montelukast Sodium | 20 | $335 |
| Omeprazole | 12 | $226 |
| Ciprofloxacin Hcl | 12 | $29 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $734 | $159,07412 claims |
| Grifols USA, LLCProlastin C | $395 | $127,45911 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $3,378 | $108,352181 claims |
| AstraZenecaSymbicort | $5,048 | $5,82017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Lafayette
- Bryan LebeanLafayette$53K
- Nethuja SalagundlaLafayette$32K
- Himani Reddy ManthenaLafayette$28K
- Hector RoblesLafayette$19K
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
- Katherine PearceBaton Rouge$12M
- Ernest ThompsonBaker$2.1M
- Brian LewisNew Orleans$2M
- Otis BarnumNatchitoches$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.